PRECIGEN, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
PRECIGEN, INC. (PGEN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $80.18 million as of 2013-12-31, per its 10-K filed 2014-03-31.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2014-03-31
- 2013-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $80.18M.
- 2013-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $73.14M.
- 2013-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $77.19M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2013-12-31 | $80.18M 10-K · filed 2014-03-31 |
| 2013-09-30 | $73.14M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $77.19M 10-Q/A · filed 2013-10-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |